Research programme: osteoporosis therapeutics - Lexicon Pharmaceuticals
Alternative Names: LX 5061Latest Information Update: 24 Jan 2018
At a glance
- Originator Lexicon Genetics
- Developer Lexicon Pharmaceuticals
- Class Antibodies; Small molecules
- Mechanism of Action Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 08 Sep 2017 Pharmacodynamics data from a preclinical trial in Osteoporosis presented at the 39th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2017)
- 13 Jan 2014 Discontinued - Preclinical for Osteoporosis in USA (PO)
- 02 May 2007 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)